Classification of systemic sclerosis in the Japanese population based on rapid progression of skin thickening

References

• Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1590–624.
   Google Scholar
• Bennett R, Bluestone R, Holt PJ, Bywaters EG. Survival in sclero-derma. Ann Rheum Dis 1971;30:581–8.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classifica-tion subsets and pathogenesis. J Ftheumatol 1988;15:202–5.
   Google Scholar
• Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75: 369–76.
   Google Scholar
• Medsger TA Jr. Scleroderma: recent advances in the treatment of progressive systemic sclerosis. Orthop Rev 1984;13:69–80.
   Google Scholar
• Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828–35.
   PubMed Web of Science ®Google Scholar
• Subcommittee for Scleroderma Criteria of the American Rheuma-tism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scle-roderma). Arthritis Rheum 1980;23:581–90.
   PubMed Web of Science ®Google Scholar
• Clements PJ, Lachenbruch P, Seibold JR, White B, Weiner S, Martin RW, et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Ftheumatol 1995;22:1281–5.
   Google Scholar
• Clements PJ, Lachenbruch PA, Swee Chen NG, Simmons M, Sterz M, Furst DE. A semiquantitative measure of cutaneous involve-ment that improves prediction of prognosis in system sclerosis. Arthritis Rheum 1990;33:1256–63.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;11:2437–44.
   Google Scholar
• Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;9:1283–9.
   Google Scholar
• Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma. Arthritis Rheum 1999;12:2660–5.
   Google Scholar
• Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot JL, et al. Is anti-topoisomerase I a serum marker of pulmonary involve-ment in systemic sclerosis? Chest 1999;116:715–20.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitu-dinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000;43:1074–84.
   Google Scholar
• Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of SjOgren's syndrome. Results of a prospective con-certed action supported by the European Community. Arthritis Rheum 1993;36:340–7.
   Google Scholar
• Fujimoto M, Shimozuma M, Yazawa N, Kubo M, Ihn H, Sato S, et al. Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/ SSA autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis 1997;56:667–70.
   PubMed Web of Science ®Google Scholar
• Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999;12:137–42.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Arnett FC, Howard FtF, Medsger TA, 23. Wright TM. Influence of ethnic background on clinical and sero-logic features in patients with systemic sclerosis and anti-DNA topoisonerase I antibody. Arthritis Rheum 1999;42:465–74.
   Google Scholar
• Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic 24. rheumatic diseases. Semin Arthritis Rheum 1995;24:323–58.
   PubMed Web of Science ®Google Scholar
• Steen VD. Epidemiology of rheumatic disease: systemic sclerosis. Rheum Dis Clin North Am 1990;16:641-54.25.
   Google Scholar
• Lee P, Langevitz P, Alderdize CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). QJM 1992; 298:139–48.
   Google Scholar
• Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. 26. Therapy for interstitial lung disease in systemic sclerosis. Arthritis Rheum 1994;9: 1290–6.
   Google Scholar
• White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophos-phamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947–54.
   Google Scholar
• Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, et al. Cyclophosphamide pulse regimen in the treat-ment of alveolitis in systemic sclerosis. J Ftheumatol 2002;29:731–6.
   Google Scholar
• Pakas I, Ioannidis JPA, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low-or high-dose prednisolone for systemic sclerosis lung disease. J Ftheumatol 2002;29:298–304.
   Google Scholar
• McSweeney PA, Nash RA, Sullivan KM, Storek J, Dansey R, Mayes MD, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002;100:1602–10.
   PubMed Web of Science ®Google Scholar